United Therapeutics Corporation
General ticker "UTHR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $16.4B
United Therapeutics Corporation follows the US Stock Market performance with the rate: 57.9%.
Estimated limits based on current volatility of 2.0%: low 355.60$, high 369.81$
Factors to consider:
- US accounted for 93.7% of revenue in the fiscal year ended 2022-12-31
- Current price 20.8% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [197.17$, 301.05$]
- 2024-12-30 to 2025-12-30 estimated range: [203.69$, 313.04$]
Financial Metrics affecting the UTHR estimates:
- Positive: Non-GAAP EPS, $ of 19.84 > 2.29
- Positive: Operating profit margin, % of 50.91 > 19.51
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Return on assets ratio (scaled to [-100,100]) of 12.08 > 7.10
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term UTHR quotes
Long-term UTHR plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $1,685.50MM | $1,936.30MM | $2,327.50MM |
| Operating Expenses | $1,129.60MM | $956.60MM | $1,142.60MM |
| Operating Income | $555.90MM | $979.70MM | $1,184.90MM |
| Non-Operating Income | $38.00MM | $-29.10MM | $89.40MM |
| Interest Expense | $18.60MM | $32.40MM | $59.30MM |
| R&D Expense | $540.10MM | $322.90MM | $408.00MM |
| Income(Loss) | $593.90MM | $950.60MM | $1,274.30MM |
| Taxes | $118.10MM | $223.30MM | $289.50MM |
| Profit(Loss) | $475.80MM | $727.30MM | $984.80MM |
| Stockholders Equity | $3,958.90MM | $4,796.70MM | $5,984.80MM |
| Inventory | $93.80MM | $102.00MM | $111.80MM |
| Assets | $5,169.10MM | $6,044.50MM | $7,167.00MM |
| Operating Cash Flow | $598.20MM | $802.50MM | $978.00MM |
| Capital expenditure | $120.80MM | $138.80MM | $230.40MM |
| Investing Cash Flow | $-486.90MM | $-811.50MM | $-719.60MM |
| Financing Cash Flow | $44.80MM | $75.40MM | $-11.90MM |
| Earnings Per Share* | $10.60 | $15.98 | $21.04 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.